Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials

CONCLUSION: Tazarotene 0.045% lotion provides statistically significant greater efficacy than vehicle in terms of lesion reduction and treatment success, with a highly favorable safety and tolerability profile in moderate-to-severe acne patients. JJ Drugs Dermatol. 2020;19(1):70-77. doi:10.36849/JDD.2020.3977 PMID: 31985914 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31985914?dopt=Abstract

Source: Journal of Drugs in Dermatology - January 28, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research